Opioid Use Disorder
Chronic relapsing disorder involving compulsive opioid use despite harmful consequences. Cannabis has insufficient high-quality evidence as an opioid-substitution therapy; some state programs nonetheless qualify OUD patients for medical cannabis access as an opioid-alternative pilot.
- 18 states
- QUALIFYING IN
- Insufficient
- EVIDENCE
- F11.20
- ICD-10
Reviewed by Dewey S. Richards
Qualifying states
What it is
Opioid use disorder (OUD) is a chronic, relapsing condition characterized by compulsive opioid use, opioid tolerance and withdrawal, and continued use despite significant harm. Three evidence-based pharmacotherapies are collectively known as Medications for Opioid Use Disorder (MOUD): methadone, buprenorphine, and naltrexone. MOUD reduces mortality, illicit drug use, and overdose risk.
Cannabis and cannabis-derived therapies
High-quality evidence for cannabis as a treatment for opioid use disorder is insufficient. Some observational studies report lower opioid prescribing and overdose rates in states that legalized medical cannabis, but causal interpretation is contested. Cannabis is not FDA-approved as MOUD and is not recommended by SAMHSA or NIDA as an opioid-substitution therapy.
Several state medical cannabis programs (notably Illinois's Opioid Alternative Pilot Program, Pennsylvania, and New York) include OUD or opioid alternative status as a qualifying basis for cannabis registry access. The clinical rationale in these programs is harm reduction rather than disease-specific cannabis efficacy: providing a regulated, non-opioid substance to patients at risk of opioid overdose.
Patients with OUD should remain engaged with established MOUD therapy and discuss cannabis use openly with their addiction medicine provider.
Frequently asked questions
Is cannabis an effective substitute for opioid medications in OUD?
The cannabis-as-opioid-substitute claim is contested. Observational studies have reported lower opioid use among some chronic-pain patients who also use cannabis, but high-quality randomized evidence is lacking. NIDA and SAMHSA do not endorse cannabis as a substitution therapy for opioid use disorder. The evidence-based treatments are methadone, buprenorphine, and naltrexone (Medications for Opioid Use Disorder, MOUD).
Is any cannabis-derived product FDA-approved for opioid use disorder?
No. No cannabis or cannabinoid product is FDA-approved for the treatment of opioid use disorder. The three FDA-approved MOUD agents (methadone, buprenorphine, and naltrexone) have strong evidence for reducing overdose mortality, illicit drug use, and treatment dropout.
Why do some state medical-cannabis programs list OUD as a qualifying condition?
A small number of states (including New Jersey, New York, Pennsylvania, and Nevada) have added opioid use disorder or opioid-alternative criteria as qualifying conditions, framed as harm-reduction pilots. State inclusion does not constitute clinical evidence of efficacy; programs that include OUD generally pair it with disclosure that cannabis is not a substitute for MOUD.
What clinical concerns apply when OUD patients use cannabis?
Cannabis can produce additive sedation with buprenorphine and methadone; respiratory depression risk is higher with concurrent benzodiazepine or alcohol use. Cannabis use disorder co-occurs with other substance-use disorders at elevated rates. Patients on MOUD should disclose cannabis use to their addiction-medicine clinician and should not discontinue evidence-based MOUD in favor of cannabis.
Sources
- SAMHSA: Medications for Opioid Use Disorderaccessed May 15, 2026
- NIH National Institute on Drug Abuse: Opioid Use Disorderaccessed May 15, 2026